Eli Lilly will buy Boston-based Verve Therapeutics, Inc. in a billion dollar deal with plans to advance Verve's new line of ...

Deal would add a potential treatment for cardiovascular disease to Eli Lilly's portfolio. The food giant says it will remove the dyes from products including Jell-O, Kool-Aid and Crystal Light before ...

B Verve Therapeutics (VERV) acquisition offers investors a 70%+ premium. See why I think this deal is beneficial to both ...

Yum Brands named Chief Financial Officer Chris Turner as its next chief executive. Eli Lilly to Acquire Verve Therapeutics for Up to $1.3 Billion Deal would add a potential treatment for ...

The deal centers around a medicine that could “shift the treatment paradigm for cardiovascular disease,” Lilly said, but also ...

The global Biosimilars Market, valued at US$32.75 billion in 2024 stood at US$35.04 billion in 2025 and is projected to ...

There are fears surrounding one of Cork's most important industries as President Donald Trump has threatened a fresh round of ...

Boston-based Verve is a rare example of a gene editing company targeting a disease that affects a large population, offering ...

Drugmakers want more clarity from the Trump administration on the potential pharmaceutical tariffs, which some companies warn ...

The efforts of CNIC and CMIE are setting the stage for this future, ensuring that Canada remains at the cutting edge of ...

Retirement dreams often hinge on a robust portfolio, with $1 million as a coveted benchmark for financial security. Achieving ...

With more than $270 billion in commitments to date, a new wave of pharmaceutical manufacturing is slated to hit the US. At least, that’s what the industry is trying to project.